Susanne P Stoof1, Fiona R M van der Klis2, Debbie M van Rooijen2, Debby Bogaert3, Krzysztof Trzciński3, Elisabeth A M Sanders4, Guy A M Berbers5. 1. Centre for Infectious Disease Control, National Institute of Public Health and the Environment (RIVM), Bilthoven, The Netherlands; Department of Immunology and Infectious Diseases, Wilhelmina Children's Hospital, University Medical Center, Utrecht, The Netherlands. Electronic address: susanne.stoof@rivm.nl. 2. Centre for Infectious Disease Control, National Institute of Public Health and the Environment (RIVM), Bilthoven, The Netherlands. 3. Department of Immunology and Infectious Diseases, Wilhelmina Children's Hospital, University Medical Center, Utrecht, The Netherlands. 4. Centre for Infectious Disease Control, National Institute of Public Health and the Environment (RIVM), Bilthoven, The Netherlands; Department of Immunology and Infectious Diseases, Wilhelmina Children's Hospital, University Medical Center, Utrecht, The Netherlands. 5. Centre for Infectious Disease Control, National Institute of Public Health and the Environment (RIVM), Bilthoven, The Netherlands. Electronic address: guy.berbers@rivm.nl.
Abstract
BACKGROUND: In several countries large-scale immunization of children and young adults with Meningococcal serogroup C (MenC) conjugate vaccines has induced long-standing herd protection. Salivary antibodies may play an important role in mucosal protection against meningococcal acquisition and carriage. AIM: To investigate antibody levels in (pre)adolescents primed 9 years earlier with a single dose of MenC-polysaccharide tetanus toxoid conjugated (MenC-TT) vaccine and the response to a booster vaccination, with special focus on age-related differences and the relation between salivary and serum antibody levels. METHODS: Nine years after priming, healthy 10- (n=91), 12- (n=91) and 15-year-olds (n=86) received a MenC-TT booster vaccination. Saliva and serum samples were collected prior to and 1 month and 1 year after vaccination. MenC-polysaccharide(MenC-PS)-specific antibody levels were measured using a fluorescent-bead-based multiplex immunoassay. RESULTS: Before the booster, MenC-PS-specific IgG and IgA levels in saliva and serum were low and correlated with age at priming. The booster induced a marked increase in salivary MenC-PS-specific IgG (>200-fold), but also in IgA (∼10-fold). One year after the booster, salivary IgG and IgA had remained above pre-booster levels in all age groups (∼20-fold and ∼3-fold, respectively), with persistence of highest levels in the 15-year-olds. MenC-PS-specific IgG and IgA levels in saliva strongly correlated with the levels in serum. CONCLUSION: Parenteral MenC-TT booster vaccination induces a clear increase in salivary MenC-PS-specific IgG and IgA levels and persistence of highest levels correlates with age. The strong correlation between serum and salivary antibody levels indicate that saliva may offer an easy and reliable tool for future antibody surveillance.
BACKGROUND: In several countries large-scale immunization of children and young adults with Meningococcal serogroup C (MenC) conjugate vaccines has induced long-standing herd protection. Salivary antibodies may play an important role in mucosal protection against meningococcal acquisition and carriage. AIM: To investigate antibody levels in (pre)adolescents primed 9 years earlier with a single dose of MenC-polysaccharidetetanus toxoid conjugated (MenC-TT) vaccine and the response to a booster vaccination, with special focus on age-related differences and the relation between salivary and serum antibody levels. METHODS: Nine years after priming, healthy 10- (n=91), 12- (n=91) and 15-year-olds (n=86) received a MenC-TT booster vaccination. Saliva and serum samples were collected prior to and 1 month and 1 year after vaccination. MenC-polysaccharide(MenC-PS)-specific antibody levels were measured using a fluorescent-bead-based multiplex immunoassay. RESULTS: Before the booster, MenC-PS-specific IgG and IgA levels in saliva and serum were low and correlated with age at priming. The booster induced a marked increase in salivary MenC-PS-specific IgG (>200-fold), but also in IgA (∼10-fold). One year after the booster, salivary IgG and IgA had remained above pre-booster levels in all age groups (∼20-fold and ∼3-fold, respectively), with persistence of highest levels in the 15-year-olds. MenC-PS-specific IgG and IgA levels in saliva strongly correlated with the levels in serum. CONCLUSION: Parenteral MenC-TT booster vaccination induces a clear increase in salivary MenC-PS-specific IgG and IgA levels and persistence of highest levels correlates with age. The strong correlation between serum and salivary antibody levels indicate that saliva may offer an easy and reliable tool for future antibody surveillance.
Authors: Mariëtte B van Ravenhorst; Gerco den Hartog; Fiona R M van der Klis; Debbie M van Rooijen; Elisabeth A M Sanders; Guy A M Berbers Journal: PLoS One Date: 2018-04-19 Impact factor: 3.240
Authors: Mariëtte B van Ravenhorst; Fiona R M van der Klis; Debbie M van Rooijen; Elisabeth A M Sanders; Guy A M Berbers Journal: BMC Med Res Methodol Date: 2019-01-05 Impact factor: 4.615
Authors: Kris E Siegers; Antonius E van Herwaarden; Jacobus H de Waard; Berenice Del Nogal; Peter W M Hermans; Doorlène van Tienoven; Guy A M Berbers; Marien I de Jonge; Lilly M Verhagen Journal: PLoS One Date: 2022-07-21 Impact factor: 3.752
Authors: Susanne P Stoof; Anne-Marie Buisman; Debbie M van Rooijen; Rianne Boonacker; Fiona R M van der Klis; Elisabeth A M Sanders; Guy A M Berbers Journal: PLoS One Date: 2015-10-12 Impact factor: 3.240